title: Could immunomodulation be used to prevent prion diseases?
abstract: All prion diseases are currently without effective treatment and are universally fatal. The underlying pathogenesis of prion diseases (prionoses) is related to an autocatalytic conformational conversion of PrP(C) (C for cellular) to a pathological and infectious conformer known as PrP(Sc) (Sc for scrapie) or PrP(Res) (Res for proteinase K resistant). The past experience with variant Creutzfeldt-Jakob disease, which originated from bovine spongiform encephalopathy, as well as the ongoing epidemic of chronic wasting disease has highlighted the necessity for effective prophylactic and/or therapeutic approaches. Human prionoses are most commonly sporadic, and hence therapy is primarily directed to stop progression; however, in animals the majority of prionoses are infectious and, as a result, the emphasis is on prevention of transmission. These infectious prionoses are most commonly acquired via the alimentary tract as a major portal of infectious agent entry, making mucosal immunization a potentially attractive method to produce a local immune response that can partially or completely prevent prion entry across the gut barrier, while at the same time producing a modulated systemic immunity that is unlikely to be associated with toxicity. A critical factor in any immunomodulatory methodology that targets a self-antigen is the need to delicately balance an effective humoral immune response with potential autoimmune inflammatory toxicity. The ongoing epidemic of chronic wasting disease affecting the USA and Korea, with the potential to spread to human populations, highlights the need for such immunomodulatory approaches.
authors.affiliation: New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA. thomas.wisniewski@nyumc.org
authors.forename: Thomas
authors.initials: T
authors.lastname: Wisniewski
authors.forename: Fernando
authors.initials: F
authors.lastname: Goñi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D002417:Cattle; D002986:Clinical Trials as Topic; D007562:Creutzfeldt-Jakob Syndrome / Q000276:immunology / Q000517:prevention & control; D003670:Deer; D016643:Encephalopathy, Bovine Spongiform / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization; D056747:Immunomodulation; D051379:Mice; D017096:Prion Diseases / Q000276:immunology* / Q000517:prevention & control*; D011328:Prions / Q000276:immunology; D012418:Ruminants; D012608:Scrapie / Q000276:immunology / Q000517:prevention & control*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology; D034081:Wasting Disease, Chronic / Q000276:immunology / Q000517:prevention & control
chemical_list: D000911:Antibodies, Monoclonal; D011328:Prions; D014612:Vaccines